Angelika Fretzen is the Wyss Institute’s Technology Translation Director and COO, applying product and entrepreneurial business development experience to the Institute’s mission of taking impactful technologies in healthcare and sustainability from the lab into their real world application. She leads a team at the Wyss that is dedicated to building a unique model of innovation, technology development and commercialization, in a community of strong collaborators within an extensive ecosystem of universities, hospitals and external business partners.She earned her Ph.D. in organic chemistry at the University of Geneva, Switzerland, and gained postdoctoral experience in the laboratory of Professor Gregory Verdine at Harvard University. Following her academic training, Angelika pursued her M.B.A. at Suffolk University, Boston, and subsequently held leadership positions at Ironwood Pharmaceuticals, and most recently at Catabasis Pharmaceuticals in Cambridge, MA, where she was Senior Vice President of Product Development. Her industry experience enabled her to gain a deep understanding of the processes involved in developing and de-risking therapeutic products from pre-clinical stages to the clinical market, including the regulatory approval process. For more than 10 years, she also served on the Board of Directors of Bridgewell, a health and human services non-profit organization serving a wide range of constituents in day programs, residential housing and clinical services.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)